Rosacea - Current View

Czech version

Authors: S. A. Ihrisky
Authors‘ workplace: Dermatovenerologická klinika 3. LF UK a FNKV, Praha přednosta prof. MUDr. Petr Arenberger, DrSc., MBA, FCMA
Published in: Čes-slov Derm, 93, 2018, No. 5, p. 163-173
Category: Reviews (Continuing Medical Education)

Overview

Rosacea is one of the most common facial dermatoses. There are four basic clinical subtypes of this disease, most often characterized by transient and persistent erythema of the face, telangiectasias, papules and pustules, or by hyperplasia of soft tissues of the face. Etiopathogenesis of rosacea is not fully understood yet, it is supposed to be multifactorial, including dysregulation of the innate immune system, role of skin commensals and neurovascular dysregulation. The review presents the current classification and approaches to the treatment of this disease, including therapeutic measures, local and systemic therapy.

Key words:

rosacea – etiopathogenesis - classification – subtypes - treatment

Sources

1. ANZENGRUBER, F., CZERNIELEWSKI, J., CONRAD, C. et al. Swiss S1 guideline for the treatment of rosacea. J Eur Acad Dermatol, 2017, 31, p. 1775–1791.

2. ALTINYAZAR, HC., KOCA R., TEKIN NS. et al. Adapalene vs metronidazol gel for the treatment of rosacea. Int J Dermatol, 2005, 44, p. 252–255.

3. ARONI, K. et al. Increased density of demodex folliculorum and evidence of delayed hypersensitivity reaction in subjects with papulopustular rosacea. J Eur Acad Dermatol Venereol, 2001, 15 (5), p. 441–44 4.

4. BAMFORD, JT. Tacrolimus effect on rosacea. J Am Acad Dermatol, 2004, 50, p. 107–108.

5. BRYLD, LE. Photodynamic therapy in a series of rosacea patients. J Eur Acad Dermatol Venerol, 2007, 21, p. 1199–1202.

6. BUECHNER, SA. Rosacea: an update. Dermatology, 2005, 10(2), p. 100–108.

7. CASAS, C. Quantification of Demodex folliculorum by PCR in rosacea and its relationship to skin innate immune activation. Exp Dermatol, 2012, 21(12), p. 906–910.

8. DEL ROSSO, JQ. Medical treatment of rosacea with emphasis on topical therapies. Expert Opin Pharmacother, 2004, 5(1), p. 5–13.

9. DEL ROSSO, JQ. et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 3: a status report on systemic therapies. Cutis, 2014, 93(1), p. 18–28.

10. DŮRA, M. et al. Lupus miliaris disseminatus faciei. Čs. derm., 2018, v tisku.

11. EGEBERG, A. Patients with Rosacea have increased risk of depression and anxiety disorders: A Danish Nationwide Cohort study. Dermatology, 2016, 232, p. 208–213.

12. ERDOGEN, FG. Efficacy of low dose isotretinoin in patients with treatment rezistant rosacea. Arch Dermatol, 1998, 134, p. 884–885.

13. GALLO, RL. et al. Standard classification and pathophysiology of rosacea: The 2017 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol, 2018,78(1), p.148–155.

14. GONSER, L. I., GONSER, C. E., SCHALLER, M. Pathogenesis, clinical picture, and current therapy of rosacea. Hautarzt, 2016, 67(1), p. 69–82.

15. GUPTA, G., Ivermectin 1% cream for rosacea. Skin Therapy Lett, 2015, 20 (4), p. 9–11.

16. HÖLZLE, E., JANSEN, T., PLEWIG, G. Morbihan disease- chronic persistent erythema and edema of the face. Hautarzt, 1995, 46(11), p. 796–798.

17. HUA, T. C. Cardiovascular comorbidities in patient with rosacea: a nationwide case-control study from Taiwan. J Am Acad Dermatol, 2015, 73, p. 249–255.

18. JANSEN, T., PLEWIG, G. Rosacea: classification and treatment. J R Soc Med, 1997, 90 (3), p. 144–150.

19. KANADA, K. N. Doxycycline indirectly inhibits proteolytic activation of tryptic kallikrein- related peptides and activation of cathelicidin. J Invest Dermatol, 2012, 132, p. 1435–1442.

20. KOCAK, K. Permethrin 5% cream vs metronidazol 0,75% gel for the treatment of papulopustular rosacea. A randomized double-blind placebo-controlled study. Dermatology, 2002, 205, p. 265–270.

21. KUČERA, J. et al. Klinický případ: erytematopapuloskvamózní postižení obličeje. Čs. derm., 2018, 2, p. 70–73.

22. LAVERS, I. Rosacea: clinical features and treatment. Nurs Stand, 2016, 30(31), p. 52–60.

23. LAYTON, A. M. Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study. J Eur Acad Dermatol Venerol, 2015, 29(12), p. 2405–2410.

24. LEHMANN, P. Rosacea: Clinical features and classification. Hautarzt, 2013, 64(7), p. 489–493.

25. MADDIN, S. A. Comparison of topical azelaic acid 20% cream and topical metronidazole 0,75% cream in the treatment of patients with papulopustular rosacea. J Am Acad Dermatol, 1999, 40, p. 961–965.

26. MAHLAPUU, M. Antimicrobial Peptides: An Emerging Category of Therapeutic Agents. Front Cell Infect Microbiol, 2016, 6, p. 194.

27. MARCINKIEWICZ, M., MAJEWSKI, S. The role of antimicrobial peptides in chronic inflammatory skin diseases. Postepy Dermatol Alergol, 2016, 33(1), p. 6–12.

28. MROWIETZ, U., KEDEM, T. H., KEYNAN, R., EINI, M., TAMARKIN, D., ROM, D., SHIRVAN, M. A Phase II, Randomized, Double-Blind Clinical Study Evaluating the Safety, Tolerability, and Efficacy of a Topical Minocycline Foam, FMX103, for the Treatment of Facial Papulopustular Rosacea. Am J Clin Dermatol, 2018, doi: 10.1007/s40257-017-0339-0. [Epub ahead of print] PubMed PMID: 29396702.

29. NIKOLOWSKI, J. Rosacea oral therapy with 13 cis retinoid acid. Hautarzt, 1980, 31, p. 660–661.

30. PARK, K. Y. Botulinum toxin for the treatment of refractory erythema and flushing of rosacea. Dermatology, 2015, 4(230), p. 299–301.

31. RAINER, B. M. Rosacea is associated with chronic systemic diseases in a skin severity-dependent manner: results of a case-control study. J Am Acad Dermatol, 2015, 73, p. 604–608.

32. REINHOLZ, M. Rosacea - S1 guideline. J Dtsch Dermatol Ges, 2013, 11(8), p. 768–780.

33. RENIERI, G. Chronic eyelid oedema and rosacea (Morbus Morbihan): diagnostic and therapeutic challenges. Klin Monbl Augenheilkd, 2011, 228(1), p. 19–24.

34. RULCOVÁ, J. Rozacea. In NEVORALOVÁ, Z. aj. Obličejové dermatózy. Praha: Mladá fronta, 2016, s. 91–121.

35. SHANLER, S. D. Successful treatment of the erythema and flushing of rosacea using a topically applied selective alpha-1-adrenergic receptor agonist, oxymetazoline. Arch Dermatol, 2007, 11(143), p. 1369–1371.

36. SLONKOVÁ, V. Rosacea a dermatitis perioralis. Čs. derm., 2009, 4, p. 183–193.

37. TAN, J. ROSCO coauthors. Updating the diagnosis, classification and assessment of rosacea by effacement of subtypes: reply from the author. Br J Dermatol, 2017, 177(2), p. 598–599.

38. TODA-BRITO, H. et al. Lupus miliaris disseminatus faciei. An Bras Dermatol, 2017, 92(6), p. 851–853.

39. TWO, A. M., Wu, W., GALLO, R. L. et al. Rosacea: Part I. Introduction, categorization, histology, pathogenesis,and risk factors. J Am Acad Dermatol, 2015,72(5), p. 749–758.

40. TWO, A. M., Wu, W., GALLO, R. L. et al. Rosacea: part II. Topical and systemic therapies in the treatment of rosacea. J Am Acad Dermatol, 2015,72(5), p. 761–770.

41. VANZUUREN, E. J. Effective and evidence-based management strategies for rosacea: summary of a Cochrane systemic review. Br J Dermatol, 2011, 165, p. 760–781.

42. WILKIN, J. et al. Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol, 2002, 46(4), p. 584–587.

Labels

Dermatology & STDs Paediatric dermatology & STDs

Cutaneous Larva Migrans – Imported Parasitic Infection

Lupus Miliaris Disseminatus Faciei. Case report

Periungual Garlic Clove Tumors. Minireview

Article was published in

Czech-Slovak Dermatology

2018 Issue 5